InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 185480

Tuesday, 10/21/2014 2:27:19 AM

Tuesday, October 21, 2014 2:27:19 AM

Post# of 345706
Harold Dvorak : Peregrine Pharmaceuticals KOL : Cancer starts with Inflammation : Part II

...chronic inflammation fuels cancer.

The association between chronic inflammation and tumor development has long been known from the early work of German pathologist Rudolph Virchow. Harvard University pathologist Dr. Harold Dvorak later compared tumors with “wounds that never heal,” noting the similarities between normal inflammation processes that characterize wound healing and tumorigenesis or tumor formation.



------------------------------------------------

Harold Dvorak : 2014 Gairdner Lecture

“VPF/VEGF: Vascular permeability & pathological
angiogenesis in tumors, wounds & chronic inflammation”


Thursday, October 23, 2014
12 noon - 1:00 p.m.
Frederic Gaspard Theatre
Basic Medical Science Building
Bannatyne Campus

YOU AND A GUEST TO THE
Thursday, October 23, 2014
12 noon - 1:00 p.m.
Frederic Gaspard Theatre
Basic Medical Science Building
Bannatyne Campus
GAIRDNER LECTURE
PRESENTED BY HAROLD F. DVORAK MD
Mallinckrodt Distinguished Professor of Pathology, Harvard Medical School
Director, Center for Vascular Biology Research, Beth Israel Deaconess Medical Center
Recipient: Canada Gairdner International Award, 2014
2014

In 1983, Dr. Dvorak and his colleagues were the first to demonstrate that tumor cells secreted vascular
endothelial growth factor (VEGF), known at the time as vascular permeability factor or VPF. This seminal
discovery provided the molecular basis for the field of angiogenesis. Dr. Dvorak went on to make the
critically important observation that tumors behave like “wounds that do not heal” in that the vascular and
stromal responses they induce closely mimic those of healing wounds. More recently, his work has
characterized the different types of blood vessels that tumors generate and the molecular mechanisms by
which they form.

Dr. Dvorak has taught for many years at the Harvard Medical School, and has lectured frequently as a
visiting professor and at numerous national and international scientific conferences. He is a fellow of the
American Association for the Advancement of Science and of the National Foundation for Cancer Research
and has served as President of the American Society for Investigative Pathology which awarded him the
2002 Rous-Whipple award the Gold-headed cane award for his scientific accomplishments. In 2005 he
received the Grand Prix Lefoulon-Delalande from the Institut de France and in 2006 the inaugural Albert
Szent-Gyorgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research (NFCR).

----------------------------------------------------------

Collegiate students to take in lecture from renowned cancer researcher

Oct 20, 2014

Dr. Harold Dvorak will deliver his student lecture "What does cancer have to do with a cut finger?" on Thursday, October 23, at 2:30 pm.

http://www.noodls.com/view/4D1B622A3E08829B10236B733BA2293344DDA8E1?5529xxx1413835002


---------------------------------------------

October 30, 2014

9:40 am–10:10am (30 mins)
VPF/VEGF: Vascular permeability & pathological angiogenesis in tumors, wounds & chronic inflammation
Dr.Harold Dvorak 2014 Canada Gairdner International Laureate,
Beth Israel Deaconess Medical Center, Boston,
MA, USA

1:05 am-1:35pm(30 mins)
Targeting immune checkpoints in cancer therapy
Dr. James Allison 2014 Canada Gairdner International Laureate,
University of Texas, Houston, USA

http://www.gairdner.org/sites/default/files/downloads/2014_canada_gairdner_recipients_lecture_october_30_2014pdf.pdf

http://www.gairdner.org/content/about-our-events

-----------------------------------------------------------






"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News